Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Advancing biotherapeutic development with transposon-based technologies
redefine-1920x640
Whitepaper

Advancing biotherapeutic development with transposon-based technologies

Stable transgene expression using plasmid-based transfection relies on recombination for integration of transgene(s) into the host cell’s genome. However, as this approach leads to random integration of the transgene it results in variability in transgene copy number and expression in the transfected cells.

With a transposon-based method a more reliable and reproducible way of integrating DNA into the host’s genome can be achieved. In this whitepaper learn about the transposon technology that can aid the streamlining of your cell line development workflows. With its simpler, faster, and consistent generation of highly producing pools, you will be able to generate representative material earlier, accelerating downstream processing development and produce adequate material for early preclinical studies.

Covering areas including:

  • Introduction to transposon technology
  • Transposons use in production and cell and gene therapy
  • The safety improvements and potential of the technology
  • Revvity's CHOSOURCE TnT Transposon technology available for license

The CHOSURCE Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Advancing biotherapeutic development with transposon-based technologies

Download Whitepaper
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.